IRF4 (Interferon Regulatory Factor 4) mRNA

Class

Antisense oligonucleotide (ASO) — frenlosirsen (ION251); hybridizes with IRF4 mRNA to block translation of IRF4 protein, preventing expression of IRF4-controlled tumor-promoter genes

Pathway

IRF4 transcriptional program (plasma-cell survival dependency)

IRF4 (Interferon Regulatory Factor 4) is a transcription factor — a protein that binds DNA and switches target genes on or off — that plays a central role in the differentiation and survival of plasma cells, the antibody-producing cells of the immune system. In certain B-cell malignancies, particularly multiple myeloma, malignant plasma cells become highly dependent on sustained IRF4 activity to maintain expression of survival and proliferation genes, a phenomenon sometimes termed transcription factor addiction. Because IRF4 functions through protein-DNA and protein-protein interactions rather than an enzymatic active site, it has historically been difficult to inhibit with conventional small molecules. Antisense oligonucleotides address this limitation by acting further upstream, at the level of messenger RNA rather than the protein itself: they hybridize, or base-pair, with IRF4 mRNA, marking it for degradation and preventing translation into protein. This strategy broadly matters for diseases in which a transcription factor is a validated driver of malignant cell survival but presents no accessible surface for standard drug binding. Modulating IRF4 this way aims to interrupt the transcriptional program sustaining malignant plasma cells, with cancers built on plasma-cell biology, such as multiple myeloma, representing the primary context of interest.